34771-39-6

Usage

Uses

Used in Pharmaceutical Industry:
6-phenyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diol is used as a potential therapeutic agent for the development of new antiviral and anticancer drugs. Its structural similarity to adenine and guanine allows it to interact with biological targets, potentially inhibiting viral replication or disrupting cancer cell processes.
Used in Medicinal Chemistry Research:
6-phenyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diol is utilized as a subject of study in medicinal chemistry to explore its unique chemical structure and the specific properties conferred by the phenyl group. This research aims to understand and exploit these properties for the design of novel therapeutic agents with improved efficacy and selectivity.
The presence of the phenyl group in 6-phenyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diol's structure may offer specific advantages in terms of molecular interactions, which could be harnessed to enhance the compound's therapeutic potential. As such, 6-phenyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diol is an interesting target for further research and development in the field of medicinal chemistry, with the goal of creating innovative treatments for various diseases.

InChI:InChI=1/C12H9N3O2/c16-11-10-9(14-12(17)15-11)6-8(13-10)7-4-2-1-3-5-7/h1-6,13H,(H2,14,15,16,17)

Upstream product

• 590-28-3 potassium cyanate 
• 237435-27-7 ethyl 3-amino-5-phenyl-1H-pyrrole-2-carboxylate 
• 237435-26-6 2-cyano-1-phenylvinyl-4-methylbenzenesulfonate 
• 614-16-4 Benzoylacetonitrile 
• 20913-05-7 (Benzoylmethylene)triphenylphosphorane 

Downstream Products

• 237435-81-3 2-chloro-6-phenyl-4-piperidylpyrrolo[3,2-d]pyrimidine 
• 237435-80-2 2,4-dichloro-6-phenylpyrrolo[3,2-d]pyrimidine 

Relevant academic research and scientific papers

A facile synthesis of pyrrolo-[3,2-d]pyrimidines from 6-azidouracils and ylide phosphoranes

A series of the title compounds, 9-deazaxanthines, was regioselectively prepared in reasonable yields as major products from the reactions of 6-azidouracils 1a,b with stabilized ester-2a,b or keto-2c ylide phosphoranes and a moderated phosphorus ylide 3, instead of the expected triazoles. Side products were also observed wherein pyrimido[5,4-g]pteridine-2,4,5,7-tetrone (15) and other fused ring systems or acyclic-substituted uracil derivatives were isolated. A comparative study on the reactivity of 1a in analogy to 1b toward phosphoranes is also described.

Compounds and methods which modulate feeding behavior and related diseases

There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists

Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.